UnitedHealth Group said it will meet with investors and analysts between September 8, 2025 and September 10 to reaffirm its adjusted 2025 earnings per share expectations previously disclosed on July 29, 2025.

8-KRegulation FD DisclosureFiled Sep 8, 2025Period of report Sep 8, 2025Summary published (UTC) Oct 13, 2026

Key points

AI summary

UnitedHealth Group said it will meet with investors and analysts between September 8, 2025 and September 10 to reaffirm its adjusted 2025 earnings per share expectations previously disclosed on July 29, 2025.
The company said the outlook incorporates closing the acquisition of Amedisys in August 2025.
UnitedHealth Group said the Amedisys acquisition is expected to be modestly dilutive to adjusted earnings per share due to financing costs and integration-related investments.
The company said the meetings may also include discussion of its strategy, market positions and recent results as previously disclosed. It added that the information in Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Reaffirming 2025 adjusted earnings per share expectations

UnitedHealth Group said it will meet with investors and analysts between September 8, 2025 and September 10 to reaffirm its adjusted 2025 earnings per share expectations previously disclosed on July 29, 2025.

Source · Based on the filing body and exhibits

Outlook incorporates Amedisys acquisition closing

The company said the outlook incorporates closing the acquisition of Amedisys in August 2025.

Source · Based on the filing body and exhibits

Acquisition impact on adjusted earnings per share

UnitedHealth Group said the Amedisys acquisition is expected to be modestly dilutive to adjusted earnings per share due to financing costs and integration-related investments.

Source · Based on the filing body and exhibits

Investor meetings discussion scope and disclosure nature

The company said the meetings may also include discussion of its strategy, market positions and recent results as previously disclosed. It added that the information in Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.